Company Overview
Snapshot
Founded in May 2022 by Yoav Rapaport and Igal Chertkow, PerMe operates with 11–50 employees. The company has raised $2 million across two funding rounds.
Business overview
PerMe is a deep-tech digital health platform focused on disruptive innovation in home DNA testing. The company develops a novel IP to convert biological samples into digital information in real-time using an affordable device, eliminating the need for traditional labs. PerMe's technology initially provides health recommendations and telehealth consultations based on biological data, with plans to apply advanced data analytics and AI/ML to collected big data for healthcare innovation, disease understanding, and new medicine discovery. It serves the digital healthcare, patient remote monitoring, and digital medical diagnostics sectors.
Strategic signal
In October and November 2024, PerMe gained significant recognition from Calcalistech.com, being highlighted as a 'Winning Startup' and for 'Revolutionizing DNA diagnostics'. This media attention underscores the market's growing interest in PerMe's innovative approach to home DNA testing and its potential to transform the digital health landscape, signaling strong validation for its deep-tech solutions.
Log in to access full profile ›Company Intelligence Q&A
- When was PerMe founded?
- PerMe was founded in May 2022.
- Who are the founders of PerMe?
- PerMe was founded by Yoav Rapaport and Igal Chertkow.
- What is PerMe's primary focus in the healthcare sector?
- PerMe focuses on developing a deep-tech digital health platform for home DNA testing, converting biological samples into digital information for health recommendations and telehealth consultations.
- How has PerMe been recognized recently?
- In October and November 2024, PerMe was featured by Calcalistech.com as a 'Winning Startup' and for 'Revolutionizing DNA diagnostics', highlighting its innovative contributions to the health tech sector.